Premium
Intracervical administration of prostaglandin E 2 ‐gel prior to therapeutic abortion: a prospective randomized double‐blind study
Author(s) -
Shalev E.,
Tsabari A.,
Edelstein S.,
Weiner E.,
Zuckerman H.
Publication year - 1988
Publication title -
international journal of gynecology and obstetrics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.895
H-Index - 97
eISSN - 1879-3479
pISSN - 0020-7292
DOI - 10.1016/0020-7292(88)90099-9
Subject(s) - medicine , placebo , vomiting , abortion , prostaglandin , cervical canal , anesthesia , pregnancy , nausea , surgery , cervix , alternative medicine , pathology , cancer , biology , genetics
Forty primigravid women due to undergo first trimster termination of pregnancy were randomly selected for intracervical application of 1 mg prostaglandin E 2 in gel or gel only as placebo. In the PGE 2 ‐gel group, a marked dilatation of the cervical canal was obtained, with post‐gel treatment mean Hegar dilatation of 11.18 mm in that group, compared to 4.4 mm in the control group (P 0.001). Moreover, 16 (80%) patients in the PGE 2 ‐gel group had a complete abortion, one (5%) patient had an incomplete abortion and in the remaining three (15%) patients, fetal demise was observed. The mean induction‐abortion interval in this group was 7.5 h. In the placebo group, none of the above effects were observed. The only side effect noted was vomiting, which occurred in five (25%) of the patients in the PGE 2 ‐gel group. Termination of pregnancy was found to be easier in the PGE 2 ‐gel group, compared to the placebo group.